Control of glioma cell migration and invasiveness by GDF-15

Oncotarget

Volumn 7, Issue 7, 2016, Pages 7732-7746

  Codó, Paula ^a   Weller, Michael ^a   Kaulich, Kerstin ^b,c   Schraivogel, Daniel ^d   Silginer, Manuela ^a   Reifenberger, Guido ^b,c   Meister, Gunter ^d   Roth, Patrick ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

GDF 15; Glioblastoma; Invasion; Serpine1; TCGA

Indexed keywords

BONE MORPHOGENETIC PROTEIN 15; MESSENGER RNA; MICRORNA; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE INHIBITOR; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; GDF15 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR 15;

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; GDF 15 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RNA INTERFERENCE; SERPINE1 GENE; SURVIVAL TIME; APOPTOSIS; BRAIN TUMOR; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; ENZYME IMMUNOASSAY; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; IMMUNOENZYME TECHNIQUES; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84958818687     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6816     Document Type: Article

References (40)

1. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15:e395-403.
2. Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M and Wischhusen J. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res. 2010; 16:3851-3859.
3. Bauskin AR, Zhang HP, Fairlie WD, He XY, Russell PK, Moore AG, Brown DA, Stanley KK and Breit SN. The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J. 2000; 19:2212-2220.
4. Mimeault M and Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol. 2010; 224:626-635.
5. Bauskin AR, Jiang L, Luo XW, Wu L, Brown DA and Breit SN. The TGF-beta superfamily cytokine MIC-1/GDF15: secretory mechanisms facilitate creation of latent stromal stores. J Interferon Cytokine Res. 2010; 30:389-397.
6. Segerer SE, Rieger L, Kapp M, Dombrowski Y, Muller N, Dietl J and Kammerer U. MIC-1 (a multifunctional modulator of dendritic cell phenotype and function) is produced by decidual stromal cells and trophoblasts. Hum Reprod. 2012; 27:200-209.
7. Breit SN, Carrero JJ, Tsai VW, Yagoutifam N, Luo W, Kuffner T, Bauskin AR, Wu L, Jiang L, Barany P, Heimburger O, Murikami MA, Apple FS, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant. 2012; 27:70-75.
8. Malyszko J, Koc-Zorawska E, Malyszko JS, Glowinska I, Mysliwiec M and Macdougall IC. GDF15 is related to anemia and hepcidin in kidney allograft recipients. Nephron Clin Pract. 2013; 123:112-117.
9. Zhou Z, Li W, Song Y, Wang L, Zhang K, Yang J, Zhang W, Su H and Zhang Y. Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLoS One. 2013;8:e78618.
10. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011; 17:581-588.
11. Shnaper S, Desbaillets I, Brown DA, Murat A, Migliavacca E, Schluep M, Ostermann S, Hamou MF, Stupp R, Breit SN, de Tribolet N and Hegi ME. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer. 2009; 125:2624-2630.
12. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98-110.
13. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF and Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992; 71:1003-1014.
14. Smith HW and Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010; 11:23-36.
15. Yoshioka H, Kamitani H, Watanabe T and Eling TE. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem. 2008; 283:33129-33137.
16. Kadowaki M, Yoshioka H, Kamitani H, Watanabe T, Wade PA and Eling TE. DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int J Cancer. 2012; 130:267-277.
17. Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M and Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013; 1:112-122.
18. Weiss T, Weller M and Roth P. Immunotherapy for glioblastoma: concepts and challenges. Curr Opin Neurol. 2015; 28:639-646.
19. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet N, Van Meir EG and Hegi ME. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene. 2002; 21:4212-4219.
20. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I and Lee JH. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 2003; 63:4648-4655.
21. Mimeault M, Johansson SL and Batra SK. Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1. Br J Cancer. 2013; 108:1079-1091.
22. Whiteside MA, Chen DT, Desmond RA, Abdulkadir SA and Johanning GL. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene. 2004; 23:744-752.
23. Proutski I, Stevenson L, Allen WL, McCulla A, Boyer J, McLean EG, Longley DB and Johnston PG. Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cells. Mol Cancer Ther. 2009; 8:2566-2574.
24. Schmierer B and Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007; 8:970-982.
25. Pickup M, Novitskiy S and Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013; 13:788-799.
26. Keeton MR, Curriden SA, van Zonneveld AJ and LoskutoffDJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem. 1991; 266:23048-23052.
27. Wilkins-Port CE, Ye Q, Mazurkiewicz JE and Higgins PJ. TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. Cancer Res. 2009; 69:4081-4091.
28. Dallas SL, Rosser JL, Mundy GR and Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem. 2002; 277:21352-21360.
29. Gomez-Duran A, Mulero-Navarro S, Chang X and Fernandez-Salguero PM. LTBP-1 blockade in dioxin receptor-null mouse embryo fibroblasts decreases TGF-beta activity: Role of extracellular proteases plasmin and elastase. J Cell Biochem. 2006; 97:380-392.
30. Czekay RP and LoskutoffDJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood). 2004; 229:1090-1096.
31. Czekay RP, Aertgeerts K, Curriden SA and LoskutoffDJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003; 160:781-791.
32. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R and Heimberger AB. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12:1113-1125.
33. Rieger J, Lemke D, Maurer G, Weiler M, Frank B, Tabatabai G, Weller M and Wick W. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem. 2008; 106:2436-2448.
34. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014; 111:409-414.
35. Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, Reifenberger G and Roth P. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget. 2014; 5:7651-7662. doi: 10.18632/oncotarget.2287.
36. Carraro G, Albertin G, Forneris M and Nussdorfer GG. Similar sequence-free amplification of human glyceraldehyde-3-phosphate dehydrogenase for real time RT-PCR applications. Mol Cell Probes. 2005; 19:181-186.
37. Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I and Weller M. Integrin control of the transforming growth factor-beta pathway in glioblastoma. Brain. 2013; 136:564-576.
38. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B and Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998; 1:611-617.
39. Dueck A, Ziegler C, Eichner A, Berezikov E and Meister G. microRNAs associated with the different human Argonaute proteins. Nucleic Acids Res. 2012; 40:9850-9862.
40. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ and von Mering C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39:D561-568.